IMIDomics will expedite the development of the antibody to exploit its potential across various immune-mediated inflammatory diseases. Credit: National Cancer Institute on Unsplash.

IMIDomics has entered an exclusive agreement to license TNAX Biopharma’s drug candidate, IMB1001, to potentially treat immune-mediated inflammatory diseases (IMIDs).

As per the deal, IMIDomics will gain access to global rights for the development, production, marketing and sub-licensing of IMB1001 from TNAX.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A humanised antibody that acts on CD226, IMB1001 is currently in the preclinical development stage.

The agreement comprises all patents, rights and information linked to the drug candidate, including its usage in humans as well as animals.

The companies did not divulge the financial terms of the deal but it is said to comprise upfront, milestone and royalty payments.

See Also:

IMIDomics chief development officer H Daniel Perez said: “In licensing this promising new drug candidate, we are demonstrating our commitment to applying our proprietary Clinical Discovery Engine in service of discovering and developing impactful medicines for IMID patients and underscoring our confidence in the potential of this therapeutic candidate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The licence of IMB1001 from TNAX accelerated our efforts to translate our scientific discoveries into meaningful therapeutic options.”

IMIDomics detected the CD226 target by leveraging its data-powered platform, Clinical Discovery Engine, to explore IMIDs’ underlying processes.

A transmembrane glycoprotein, CD226 has a key role in the immune response.

IMB1001 is said to possess wider applicability across various ailments, especially for patients who are unresponsive or intolerant to the existing standard of care treatments.

IMIDomics will expedite the development of this antibody to exploit its potential across various IMIDs.